Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Poland

Coordination and Support Action · Running

PERFECTION In search of PERFECTION – the phenomenon of unnatural amino acids in chemical biology for biological and medical applications

Coordinator
Instytut Chemii Fizycznej Polskiej Akademii Nauk, Poland
Runs
1 March 2025 to 28 February 2030
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
Coordination and Support Action
Grant agreement
101186564

What the project is doing

In the project's own words, from its summary on CORDIS.

PERFECTION foresees launching the Department of Chemical Biology for Biological & Medical Applications (DCB) at the Institute of Physical Chemistry PAS (IChF) by Prof Marcin Drg (ERA Chair holder, ECh), an excellent biological chemist with expertise in combinatorial chemistry of proteolytic enzymes and their applications. IChF is renowned for its methods of measuring and analysing physical, chemical and biological systems.

Yet, we lack biologically relevant molecules to improve these methods and tackle complex health issues. We also need more recognition from partners to join project consortia and better exploit our research results. Under the project, DCB will undertake close collaboration with IChFs researchers, supplying them with novel compounds (modified peptides with unnatural amino acids, UAA) for broad-ranging studies on new chemical markers to target diverse diseases.

DCB will also offer leading structures to support the creation of UAA-based drugs, similar to those in Nirmatrelvir/Paxlovid (a SARS-CoV-2 drug that uses UAA discovered by Prof Drg and team; Nature Chem Biol, 2021). The project measures involve revamping the IChF Research Agenda, training, guidance, and mentorship of IChF researchers by ECh, coupled with enhanced networking with academic and industry partners. We will also tackle the shortage of international researchers available for IChF by setting up training research programmes on drug/diagnostics delivery.

To further solidify our partnerships with stakeholders, we will refine IChFs research management practices, notably in IP management and stakeholder communication. Our efforts will be bolstered by support from 14 research institutions and 6 companies (i.a., Stanford University School of Medicine, Genentech, Kintsugi) that have committed to the project. The ultimate project goal is to establish IChF as a premier research entity recognised for cutting-edge chemical tools for biological chemistry applications and their market launch.

Topics

Who is involved

OrganisationCityCountryRole
Instytut Chemii Fizycznej Polskiej Akademii NaukWarszawaPolandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI